Pluristem Therapeutics Inc.
- Home
- Companies
- Pluristem Therapeutics Inc.
- Videos
- Topline Phase I Results in Pluristem`s ...
Topline Phase I Results in Pluristem`s Hematology Program - Video
Pluristem presents topline Phase I results from its hematology program, which is the first to study PLX-R18 in humans.
The video provides first-hand interviews from Dr. Nitsan Halevy, Chief Medical Officer, and Dr. Racheli Ofir, VP Research & Intellectual Property, sharing insights on PLX-R18's unique mechanism of action and therapeutic potential for the treatment of hematology deficiencies.
Pluristem's PLX R-18 cell therapy has the potential to generate improved blood counts in all three blood cell lineages.
About Us:
Pluristem Therapeutics Inc. (NASDAQ, TASE: PSTI) is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late-stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off-the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a Company owned and operated GMP-certified manufacturing and research facility; strategic relationships with major research institutions; and a seasoned management team. Learn more about Pluristem at https://www.pluristem.com/.
The video provides first-hand interviews from Dr. Nitsan Halevy, Chief Medical Officer, and Dr. Racheli Ofir, VP Research & Intellectual Property, sharing insights on PLX-R18's unique mechanism of action and therapeutic potential for the treatment of hematology deficiencies.
Pluristem's PLX R-18 cell therapy has the potential to generate improved blood counts in all three blood cell lineages.
About Us:
Pluristem Therapeutics Inc. (NASDAQ, TASE: PSTI) is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late-stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off-the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a Company owned and operated GMP-certified manufacturing and research facility; strategic relationships with major research institutions; and a seasoned management team. Learn more about Pluristem at https://www.pluristem.com/.
Most popular related searches